Skip to main content
Clinical Trials/NCT03674450
NCT03674450
Withdrawn
Not Applicable

A Pilot Study at a Single Institution of Heart Rate Variability Biofeedback on Lung Cancer Patients Receiving Radiation Thearpy

Abramson Cancer Center at Penn Medicine1 site in 1 countryJanuary 2, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non Small Cell Lung Cancer
Sponsor
Abramson Cancer Center at Penn Medicine
Locations
1
Primary Endpoint
EORTC QLQ-C30 Questionnaire
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to examine the effects of heart-rate variability biofeedback training on lung cancer patients receiving definitive radiation therapy. The target population consists of non-small cell lung cancer (NSCLC) patients receiving 6 weeks of radiation therapy. The study will utilize the Physiolab GP8 heart rate variability and respiration system to collect data as well as several survey instruments to analyze quality of life measures. The goal is to show the HRV training can improve certain QOL measures like anxiety and sleep quality.

Registry
clinicaltrials.gov
Start Date
January 2, 2019
End Date
April 11, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants must be older than 18 years of age
  • Both women and men of all ethnic background are eligible to participate in the study.
  • Must be diagnosed with non-small cell lung cancer and receiving 6 weeks of radiation therapy.
  • Must be available and willing to participate in 4, approximately 1 hour HRV biofeedback treatment sessions.
  • Signed informed consent

Exclusion Criteria

  • Participant is younger than 18 or older than 70
  • Diagnosed with early stage NSCLC
  • Patients who are pregnant
  • Patients with cardiac arrhythmias
  • Patients with Pacemakers
  • Patients taking beta-blockers
  • Patients with any major mental illness, cognitive impairment
  • Incapable of giving informed consent

Outcomes

Primary Outcomes

EORTC QLQ-C30 Questionnaire

Time Frame: 2 years

Questionnaire developed to assess the quality of life of cancer patients. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Secondary Outcomes

  • Pittsburgh Sleep Quality Index (PSQI)(2 years)

Study Sites (1)

Loading locations...

Similar Trials